For gastrointestinal symptoms , which represent the most common side effects: Eat smaller, more frequent meals rather than large portions Avoid high-fat, greasy, or spicy foods that may exacerbate nausea Stay well-hydrated, particularly if experiencing vomiting or diarrhoea Consider eating bland foods (toast, crackers, rice) when nauseous Take anti-emetic medications if prescribed by your doctor Allow adequate time between dose escalations (typically 4 weeks minimum) Seek medical advice promptly if experiencing persistent or severe vomiting or diarrhoea, as these can lead to dehydration and acute kidney injury Injection site management: Rotate injection sites between abdomen, thigh, and upper arm Allow the medication to reach room temperature before injecting Use proper injection technique as demonstrated by your healthcare provider Apply a cold compress if irritation occurs Hypoglycaemia prevention: Monitor blood glucose levels as advised, particularly when initiating treatment Recognise early warning signs (trembling, sweating, confusion, palpitations) Carry fast-acting carbohydrates (glucose tablets, sugary drinks) Discuss dose adjustments of other diabetes medications with your clinician For women using oral contraceptives: Be aware that tirzepatide can reduce the effectiveness of oral contraceptives during initiation and after each dose increase Use additional contraception for 4 weeks after starting treatment and for 4 weeks after each dose escalation Consider non-oral contraceptive methods as an alternative General wellbeing strategies: Maintain regular follow-up appointments to monitor treatment response and side effects Keep a symptom diary to identify patterns and triggers Ensure adequate hydration (aim for 68 glasses of water daily) Report persistent or worsening symptoms promptly Report suspected adverse reactions via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) NICE guidance (NG28 for type 2 diabetes) emphasises the importance of individualised treatment approaches
Is dehydration listed as a side effect in tirzepatide clinical trials
Its also used in ways not officially approved by regulatory health authorities such as slowing down disease progression in cystic fibrosis patients
(Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced positive one-year results from its REMAIN-1 Midpoint Cohort (Midpoint Cohort)
